ArticleIranian journal of basic medical sciences2026
Liquiritin ameliorates atherosclerosis in ApoE
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Atherosclerosis (AS) and dyslipidemia are major contributors to cardiovascular disease; however, safe and effective therapeutic strategies remain limited. Liquiritin, a natural flavonoid, exhibits potential metabolic and cardiovascular benefits in human beings. This study investigated the effects of liquiritin on AS, lipid metabolism, and hepatic steatosis in high-fat diet (HFD)-induced ApoE Materials and Methods: Mice were intraperitoneally administered liquiritin (20 mg/kg/day) for 12 weeks. Histological and biochemical analyses revealed that chronic liquiritin treatment did not induce hepatotoxicity, nephrotoxicity, or growth impairment, as evidenced by preserved liver and kidney architecture, unchanged serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and blood urea nitrogen (BUN) levels, and stable body weight. Results: Liquiritin markedly attenuated aortic root plaque formation, lipid deposition, and fibrotic areas ( Conclusion: These findings demonstrate that liquiritin protects against AS and hepatic lipid accumulation by modulating SIRT1-mediated lipid metabolism (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.